Skip to main content

Table 2 Beta-blocker medication (full analysis set)

From: Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers

 

Total patients (N = 3589)

Medication

Patients who took any beta-blocker medications, n (%)

1269 (35.4)

Selective beta-blocking agents

889 (24.7)

 Metoprolola

627 (17.4)

 Atenolola

171 (4.8)

 Bisoprolola

56 (1.6)

 Nebivolola

34 (0.9)

 Acebutolol

1 (< 0.1)

Non-selective beta-blocking agents

391 (10.9)

 Carvedilol

314 (8.7)

 Propranolola

39 (1.1)

 Sotalola

24 (0.7)

 Labetalol

9 (0.3)

 Nadolol

4 (0.1)

 Pindolol with hydrochlorothiazide

1 (< 0.1)

  1. Full analysis set (N = 3589); included all patients randomized to treatment who received ≥ 1 dose of study drug
  2. Beta-blocker medication was taken before randomization and continued after the first study dose. Of note, up to 11 patients took multiple beta-blockers across this period
  3. N number of subjects in treatment group, n number of subjects in category
  4. aIncludes different salt conjugates and diuretic combinations